Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
MindMed announces that the FDA has placed "clinical hold" on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).
Novamind announces a definitive agreement to acquire Arizona-based Foundations for Change, PLC.
Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now